Showing 1 to 2 of 2

Shareholders pleased with Synlait Milk results

News Item
Shareholders who attended Synlait Milk’s Annual Meeting of Shareholders today were pleased with the company’s solid financial performance and continued progress in the 2014 financial year.

Synlait Milk receives China approval to manufacture retail-ready infant formula

News Item
Synlait Milk is now a registered manufacturer of retail-ready infant formula for export to China, following approval from the Certification and Accreditation Administration of the People's Republic ...

Synlait Milk posts $19.6 million NPAT for FY2014

News Item
Synlait Milk has posted a $19.6 million net profit after tax (NPAT) for the year ending 31 July 2014, an increase of 70% compared to the $11.5 million NPAT for FY2013, and in line with its ...

Synlait Milk receives MPI approval

News Item
Synlait Milk has received approval of its Risk Management Programme from the Ministry for Primary Industries (MPI) for its dry blending and consumer packaging plant.

Jeremy Burgess

Our People

Strong demand for Synlait Milk’s lactoferrin

News Item
Synlait Milk expects strong global demand for its lactoferrin to continue since it began commercially producing and selling the valuable milk protein earlier this year.

Analyst & Media Policy

We have several analysts and institutions that follow our shares and may issue commentary or reports on us and our performance from time to time.

First farm environment plan template approved

News Item
Environment Canterbury announced its approval of the first farm environment plan template under the proposed Land & Water Regional Plan.

Synlait Lactoferrin

Lactoferrin has been recognised for its health benefits. It has a range of bio-active functions, including iron binding, anti-microbial, anti-inflammatory and antioxidant activity.

Synlait Milk realigns senior team to better serve its customers

News Item
Synlait Milk has appointed Mike Lee to the newly created role of General Manager Sales reporting to the Managing Director Dr John Penno.